Cancers (Dec 2022)
Serum Extracellular Vesicle-Derived microRNAs as Potential Biomarkers for Pleural Mesothelioma in a European Prospective Study
- Elisabetta Casalone,
- Giovanni Birolo,
- Barbara Pardini,
- Alessandra Allione,
- Alessia Russo,
- Chiara Catalano,
- Manlio Mencoboni,
- Daniela Ferrante,
- Corrado Magnani,
- Marika Sculco,
- Irma Dianzani,
- Federica Grosso,
- Dario Mirabelli,
- Rosa Angela Filiberti,
- Ottavio Rena,
- Carlotta Sacerdote,
- Miguel Rodriguez-Barranco,
- Karl Smith-Byrne,
- Salvatore Panico,
- Claudia Agnoli,
- Theron Johnson,
- Rudolf Kaaks,
- Rosario Tumino,
- José María Huerta,
- Elio Riboli,
- Alicia K Heath,
- Camino Trobajo-Sanmartín,
- Matthias B. Schulze,
- Calogero Saieva,
- Pilar Amiano,
- Antonio Agudo,
- Elisabete Weiderpass,
- Paolo Vineis,
- Giuseppe Matullo
Affiliations
- Elisabetta Casalone
- Department of Medical Sciences, University of Turin, 10126 Turin, Italy
- Giovanni Birolo
- Department of Medical Sciences, University of Turin, 10126 Turin, Italy
- Barbara Pardini
- Italian Institute for Genomic Medicine, IIGM, 10060 Candiolo, Italy
- Alessandra Allione
- Department of Medical Sciences, University of Turin, 10126 Turin, Italy
- Alessia Russo
- Department of Medical Sciences, University of Turin, 10126 Turin, Italy
- Chiara Catalano
- Department of Medical Sciences, University of Turin, 10126 Turin, Italy
- Manlio Mencoboni
- Medical Oncology, ASL 3 Genovese, Villa Scassi Hospital, 16149 Genoa, Italy
- Daniela Ferrante
- Unit of Medical Statistics, Department of Translational Medicine, University of Eastern Piedmont and Cancer Epidemiology, CPO Piemonte, 28100 Novara, Italy
- Corrado Magnani
- Unit of Medical Statistics, Department of Translational Medicine, University of Eastern Piedmont and Cancer Epidemiology, CPO Piemonte, 28100 Novara, Italy
- Marika Sculco
- Department of Health Sciences, University of Eastern Piedmont, 28100 Novara, Italy
- Irma Dianzani
- Department of Health Sciences, University of Eastern Piedmont, 28100 Novara, Italy
- Federica Grosso
- Mesothelioma Unit, AO SS. Antonio e Biagio e Cesare Arrigo, 15121 Alessandria, Italy
- Dario Mirabelli
- Unit of Cancer Epidemiology, Città della Salute e della Scienza, University-Hospital and Center for Cancer Prevention (CPO), 10126 Turin, Italy
- Rosa Angela Filiberti
- Clinical Epidemiology, IRCCS AOU San Martino IST, 16100 Genoa, Italy
- Ottavio Rena
- Unit of Thoracic Surgery, University of Novara, 28100 Novara, Italy
- Carlotta Sacerdote
- Unit of Cancer Epidemiology, Città della Salute e della Scienza, University-Hospital and Center for Cancer Prevention (CPO), 10126 Turin, Italy
- Miguel Rodriguez-Barranco
- Escuela Andaluza de Salud Pública (EASP), 18012 Granada, Spain
- Karl Smith-Byrne
- Cancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford OX3 7LF, UK
- Salvatore Panico
- EPIC Centre of Naples, Dipartimento di Medicina Clinica e Chirurgia, Federico II University, 80100 Napoli, Italy
- Claudia Agnoli
- Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 Milano, Italy
- Theron Johnson
- Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany
- Rudolf Kaaks
- Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany
- Rosario Tumino
- Hyblean Association for Epidemiology Research AIRE ONLYS, 97100 Ragusa, Italy
- José María Huerta
- Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), 28029 Madrid, Spain
- Elio Riboli
- Department of Epidemiology and Biostatistics, School of Public Health, Imperial College, London W2 1PG, UK
- Alicia K Heath
- Department of Epidemiology and Biostatistics, School of Public Health, Imperial College, London W2 1PG, UK
- Camino Trobajo-Sanmartín
- Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), 28029 Madrid, Spain
- Matthias B. Schulze
- Department of Molecular Epidemiology, German Institute of Human Nutrition Potsdam-Rehbruecke, 14558 Nuthetal, Germany
- Calogero Saieva
- Cancer Risk Factors and Life-Style Epidemiology Unit, Institute for Cancer Research, Prevention and Clinical Network (ISPRO), 50139 Florence, Italy
- Pilar Amiano
- Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), 28029 Madrid, Spain
- Antonio Agudo
- Unit of Nutrition and Cancer, Catalan Institute of Oncology—ICO, 08908 L’Hospitalet de Llobregat, Spain
- Elisabete Weiderpass
- International Agency for Research on Cancer, World Health Organization, 69372 Lyon, France
- Paolo Vineis
- MRC Centre for Environment and Health, School of Public Health, Imperial College, London W2 1PG, UK
- Giuseppe Matullo
- Department of Medical Sciences, University of Turin, 10126 Turin, Italy
- DOI
- https://doi.org/10.3390/cancers15010125
- Journal volume & issue
-
Vol. 15,
no. 1
p. 125
Abstract
Malignant pleural mesothelioma (MPM) is an aggressive cancer with a dismal prognosis. Early therapeutic interventions could improve patient outcomes. We aimed to identify a pattern of microRNAs (miRNAs) as potential early non-invasive markers of MPM. In a case-control study nested in the European Prospective Investigation into Cancer and Nutrition cohort, we screened the whole miRNome in serum extracellular vesicles (EVs) of preclinical MPM cases. In a subgroup of 20 preclinical samples collected five years prior MPM diagnosis, we observed an upregulation of miR-11400 (fold change (FC) = 2.6, adjusted p-value = 0.01), miR-148a-3p (FC = 1.5, p-value = 0.001), and miR-409-3p (FC = 1.5, p-value = 0.04) relative to matched controls. The 3-miRNA panel showed a good classification capacity with an area under the receiver operating characteristic curve (AUC) of 0.81 (specificity = 0.75, sensitivity = 0.70). The diagnostic ability of the model was also evaluated in an independent retrospective cohort, yielding a higher predictive power (AUC = 0.86). A signature of EV miRNA can be detected up to five years before MPM; moreover, the identified miRNAs could provide functional insights into the molecular changes related to the late carcinogenic process, preceding MPM development.
Keywords